Traditional biochemical methods of studying human gene mutations are often laborious and costly. Now bioengineers at the ...

The study by Li et al. provides fundamental findings supported by convincing evidence that they defined cellular reprogramming of androgen receptor in neuroendocrine prostate cancer (NEPC). The ...

Joe DePinto, MBA, head of cell, gene and advanced therapies at McKesson , met with MHE at the annual Asembia Specialty ...

Regeneron Pharmaceuticals has received a total of 10 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $797.9, the consensus suggests a potential 32.4% ...

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...